NCT04502446View on ClinicalTrials.gov

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

PHASE1TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
T Cell Lymphoma
Interventions
BIOLOGICAL

CTX130

CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.

Trial Locations (10)

2050

Research Site 3, Sydney

10065

Research Site 9, New York

10467

Research Site 8, The Bronx

33124

Research Site 4, Miami

77030

Research Site 1, Houston

84112

Research Site 6, Salt Lake City

91010

Research Site 2, Duarte

94305

Research Site 5, Stanford

06520

Research Site 10, New Haven

M5G 2C1

Research Site 7, Toronto

Sponsors
All Listed Sponsors
lead

CRISPR Therapeutics AG

INDUSTRY

NCT04502446 - A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | Biotech Hunter | Biotech Hunter